Germany’s Grunenthal Shuffles Leadership Team As CEO Stock Departs
This article was originally published in The Pink Sheet Daily
Germany’s family-owned pain specialty company Grunenthal – already bracing for an expected fall in sales due to the loss of exclusivity on its best-selling product – now finds itself searching for a new CEO as well.
You may also be interested in...
Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.